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ABSTRACT
Objectives: Risk factors for cardiovascular events are
well established in general populations and those with
diabetes but have been sparsely studied in impaired
glucose tolerance (IGT). We sought to identify
predictors of (1) a composite cardiovascular outcome
(cardiovascular death, non-fatal myocardial infarction
and non-fatal stroke) and (2) cardiovascular death,
among patients with IGT.
Design: We studied participants enrolled in the
Nateglinide and Valsartan in Impaired Glucose
Tolerance Outcomes Research (NAVIGATOR) trial.
Predictors of cardiovascular events were identified in
observational analyses.
Setting: Clinical trial participants in 40 countries.
Participants: 9306 participants with biochemically
confirmed IGT at high risk of cardiovascular events
participated in NAVIGATOR.
Primary and secondary outcome measures:
Cox proportional hazard regression models were
constructed using variables (demographic data,
medical history, clinical features, biochemical results
and ECG findings) recorded at baseline to identify
variables associated with and predictive of
cardiovascular events.
Results: Over 6.4 years, 639 (6.9%) participants
experienced a cardiovascular event, and 244 (2.6%)
cardiovascular death. While predictors of both
outcomes included established risk factors such as
existing cardiovascular disease, male gender, older
age, current smoking status and higher low-density
lipoprotein cholesterol, other variables such as reduced
estimated glomerular filtration rate, previous
thromboembolic disease, atrial fibrillation, higher
urinary albumin/creatinine ratio and chronic obstructive
pulmonary disease were also important predictors.
Glycaemic measures were not predictive of
cardiovascular events. c-Statistics for predicting
cardiovascular events and cardiovascular death were
0.74 and 0.82, respectively. This compares with
c-statistics for cardiovascular events and cardiovascular
death of 0.65 and 0.71, respectively, using the
classical Framingham risk factors of age, total
cholesterol, high-density lipoprotein cholesterol,
systolic blood pressure, treatment for hypertension and
smoking status.
ARTICLE SUMMARY
Article focus
▪ Predictors of cardiovascular events have been
intensively studied in general populations and in
patients with diabetes but less well studied in
those with impaired glucose tolerance (IGT).
▪ The Nateglinide and Valsartan in Impaired
Glucose Tolerance Outcomes Research
(NAVIGATOR) study is the largest trial yet con-
ducted in those with biochemically confirmed
IGT and major cardiovascular events were adjudi-
cated endpoints, providing an opportunity to
study the predictors of risk.
Key messages
▪ Predictors of cardiovascular events in IGT
included established risk factors such as existing
cardiovascular disease, male gender, older age,
current smoking status and higher low-density
lipoprotein cholesterol.
▪ Other variables such as reduced estimated glom-
erular filtration rate, previous thromboembolic
disease, atrial fibrillation, higher urinary albumin/
creatinine ratio and chronic obstructive pulmon-
ary disease were also important predictors.
▪ Glycaemic measures (glycated haemoglobin,
fasting plasma and 2 h glucose) were not pre-
dictive of cardiovascular events.
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Conclusions: The most powerful independent predictors of
cardiovascular events in IGT included both established risk factors
and other variables excluding measures of glycaemia, allowing
effective identification of high-risk individuals.
Individuals with impaired glucose tolerance (IGT) are at
an elevated risk of cardiovascular events compared with
normoglycaemic individuals.1 2 Consequently, identiﬁca-
tion of cardiovascular risk factors in subjects with IGT, an
increasingly common condition,3 should improve risk pre-
diction of cardiovascular events and help target interven-
tions to reduce risk. Cardiovascular risk factors are already
well established in general populations and in patients with
diabetes. Algorithms to predict risk of future cardiovascular
events in the general population commonly include clas-
sical risk factors such as older age, male sex, smoking,
elevated blood pressure, dyslipidaemia, diabetes and family
history of premature cardiovascular disease.4 Recently,
other factors such as microalbuminuria, glycated haemo-
globin (HbA1c), atrial ﬁbrillation, chronic kidney disease,
lower-socioeconomic status, abdominal obesity and higher
body mass index have been added to improve risk estima-
tion.5 Predictive models in subjects with established dia-
betes include these and additional variables like diabetes
duration, anthropometric measures and presence and
severity of microvascular complications.6–9 However, risk
factors independently associated with cardiovascular events
have not been studied in detail in IGT and little is known
about the distribution of absolute risk of cardiovascular
events in IGT.
The aims of this study were to identify independent pre-
dictors of two outcomes, namely a composite cardiovascu-
lar endpoint (cardiovascular death, non-fatal myocardial
infarction and non-fatal stroke) and cardiovascular death,
respectively, in individuals with IGT, to clarify the distribu-
tion of absolute risk of events in this population and to
assess the use of cardiovascular risk-reducing therapies
according to absolute risk categories using data from the
Nateglinide and Valsartan in Impaired Glucose Tolerance
Outcomes Research (NAVIGATOR) trial.
METHODS
NAVIGATOR (ClinicalTrials.gov number, NCT00097786)
was a double-blinded randomised clinical trial with a
two-by-two factorial design which assessed the ability of
two agents, nateglinide and valsartan, to respectively
reduce major cardiovascular events and new-onset dia-
betes in participants with IGT. Details of the trial includ-
ing the protocol, results and design were published
previously.10–12 In brief, a total of 9306 participants from
40 countries participated in the trial for a median of
6.4 years. Each participant was randomised to treatment
with nateglinide or placebo plus valsartan or placebo,
and participants received a lifestyle modiﬁcation
programme.
Participants
On the basis of general criteria including age and
history of cardiovascular disease, possible research parti-
cipants were asked to attend screening clinics to formally
assess their potential enrolment. Men and women with
IGT were eligible if they had one or more cardiovascular
risk factors and were aged ≥55 years or if they had estab-
lished cardiovascular disease and were aged ≥50 years.
Inclusion and exclusion criteria are described in previ-
ous publications.10–12 Potentially eligible subjects under-
went an oral 75 g glucose tolerance test (OGTT) and
IGT was deﬁned as a 2 h postchallenge glucose value
of 7.8–11.0 mmol/l (and fasting plasma glucose of
5.3–6.9 mmol/l). Subjects taking an ACE inhibitor for
hypertension (patients taking an ACE inhibitor for
other conditions (coronary artery disease, left ventricu-
lar dysfunction, macroalbuminuria, peripheral arterial
disease, stroke or transient ischaemic attack) were not
excluded) or an angiotensin II-receptor blocker (ARB)
who were unable or unwilling to stop the drug were
excluded. Those taking an ACE inhibitor or ARB for
these other conditions were required to stop treatment
at least 4 weeks prior to participation. All NAVIGATOR
participants provided written informed consent.
Cardiovascular endpoints
We focused on the prediction of two cardiovascular end-
points: (1) a composite cardiovascular outcome of car-
diovascular mortality, non-fatal myocardial infarction or
non-fatal stroke (this differs from the extended compos-
ite cardiovascular outcome used as the primary endpoint
in the trial) and (2) cardiovascular death. Endpoints
were adjudicated by an independent committee blinded
to treatment allocation.
Statistical analysis
Continuous baseline variables were summarised as
mean±SD, except where noted otherwise. Between
groups, comparisons were performed using t tests
for normally distributed data or non-parametric tests
(Wilcoxon rank sum) otherwise. Categorical variables
were summarised as counts and percentages and were
compared using χ2 tests or Fisher’s exact test.
Prognostic model building: Data from all NAVIGATOR
participants were included to construct separate models
for (1) the composite cardiovascular outcome and
ARTICLE SUMMARY
Strengths and limitations of this study
▪ NAVIGATOR was a prospective study that included over 9000
participants with biochemically confirmed IGT and accumulated
a large number of cardiovascular endpoints.
▪ Participants in the study were well phenotyped at baseline in
the study.
▪ The results from NAVIGATOR may not be applicable to all with
IGT as participants were a high-risk population based on other
cardiovascular risk factors.
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(2) cardiovascular death. Thirty-eight candidate vari-
ables collected at baseline, consisting of demographics,
clinical measurements, medical history, investigator
reported ECG (normal, clinically insigniﬁcant abnormal-
ity or clinically signiﬁcant abnormality) and laboratory
results, were included (listed in table 1). Cox propor-
tional hazard regression models were developed to
evaluate the relationships between these candidate vari-
ables and both cardiovascular outcomes, and these were
added to the model by forward selection at p<0.05.
Missing data were handled by single and multiple imput-
ation, which provided consistent results and single
imputation is reported herein. Less than 3% of data
were missing for all variables except for HbA1c where
15% were missing. Variables were checked for linearity
and proportional hazards. Linear splines were used to
account for non-linear relationships of relevant continu-
ous variables with cardiovascular outcomes. The statis-
tical strength of the contribution of each variable to
prediction of the cardiovascular outcome was expressed
as the p value corresponding to the Wald χ2 statistic, a
measure allowing direct comparison of the predictive
information provided by each variable. In sensitivity ana-
lyses, study treatments (nateglinide and valsartan) were
forced into the models for both endpoints. Models
using only classical-risk factors from the Framingham
equations (age, total cholesterol, high-density lipopro-
tein (HDL), systolic blood pressure (SBP), treatment for
hypertension and smoking status) were also developed
to allow comparison with the variable-rich models.
A calibration plot comparing predicted and observed
risk of a cardiovascular event was generated to assess the
risk distribution in the NAVIGATOR trial population.
Assessment of appropriateness of care
We aimed to assess whether participants at progressively
higher risk of cardiovascular events were treated more
intensively with risk-reducing agents. Participants were
divided into those with and without cardiovascular
disease at baseline. Those without baseline cardiovascu-
lar disease were further divided into low (<2.5% with the
composite cardiovascular outcome per 5 years), inter-
mediate (2.5–10% per 5 years) and high (>10% per
5 years) risk based on subsequent occurrence of cardio-
vascular events. Prescriptions of cardiovascular risk low-
ering medications at baseline were tabulated to allow
direct comparison.
p Values <0.05 were considered statistically signiﬁcant
and all p values were two sided. Analyses were con-
ducted using SAS V.9.2 software (Chicago, Illinois, USA).
There are no additional data available.
RESULTS
Baseline results for the 9306 participants in NAVIGATOR
are provided in table 1, divided into those who did and
did not experience the composite cardiovascular
outcome. Average age was 64 years, 6131 (66%) had no
history of cardiovascular disease at baseline, and mean
HbA1c was 5.8%. During median follow-up of 6.4 years,
639 (6.9%) experienced the composite cardiovascular
outcome (event rate 5.9% (95% CI 5.4% to 6.4%) aver-
aged over 5 years) and 244 (2.6%) participants died from
cardiovascular causes (event rate 2.0 (95% CI 1.7 to 2.3)
averaged over 5 years). When limited to the subgroup
with no history of cardiovascular disease, 248 (4.0%)
experienced a composite cardiovascular outcome event.
Risk factors independently associated with the composite
cardiovascular outcome
In the multivariable Cox model, history of coronary
heart disease (present in 28%) was the strongest pre-
dictor and was associated with a doubling of risk (see
table 2). Male sex was associated with 89% increase in
cardiovascular risk while older age was associated with
32% higher risk per decade. Other major predictors
included current smoking status, physician-reported clin-
ically signiﬁcant abnormality on ECG, higher low-density
lipoprotein (LDL) cholesterol, history of cerebrovascular
disease and lower estimated glomerular ﬁltration rate
(eGFR). Other variables independently associated with
cardiovascular events were history of peripheral arterial
disease, history of pulmonary embolism or deep venous
thrombosis, higher urine albumin-to-creatinine ratio
(UACR), geographic area (Latin America vs North
America), higher pulse pressure, history of chronic
obstructive pulmonary disease (COPD), black race (vs all
other races), history of heart failure, lower haemoglobin,
lower serum sodium, higher waist circumference and
atrial ﬁbrillation. None of fasting plasma glucose, 2 h
postchallenge glucose or HbA1c was independently asso-
ciated with the composite cardiovascular outcome. The c-
statistic for this variable-rich prognostic model was 0.74.
When study treatments were forced into the model,
neither displayed a signiﬁcant association and the impact
on the predictive capabilities of the other variables was
negligible (data not shown). The c-statistic for a predict-
ive model including only classical risk factors (age, total
cholesterol, HDL-cholesterol, SBP, treatment for hyper-
tension and smoking status) was 0.65.
Risk factors independently associated with
cardiovascular death
Older age was the strongest predictor of cardiovascular
death (77% higher risk per 10 years; see table 3). Both
history of coronary heart disease and the presence of
congestive heart failure (present in 4% of participants)
were associated with a doubling in risk. Other variables
independently associated with cardiovascular death were
geographical area (Latin America vs North America,
Other vs North America), male sex, current smoking
status, clinically signiﬁcant or insigniﬁcant abnormalities
on ECG, lower eGFR, higher UACR, history of cerebro-
vascular disease, atrial ﬁbrillation, lower haemoglobin,
history of COPD, peripheral arterial disease and history
of renal dysfunction. The c-statistic for this variable-rich
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Table 1 Baseline characteristics of 9306 participants with impaired glucose tolerance in the NAVIGATOR trial stratified by occurrence
of events, namely cardiovascular death, non-fatal myocardial infarction and non-fatal stroke
Variable* All
Experienced cardiovascular
event during trial
p ValueNo Yes
N 9306 8667 639
Age (years) 63.8 (6.8) 63.6 (6.8) 66.0 (7.6) <0.001
Male gender 4595 (49%) 4169 (48) 426 (67) <0.001
Race
Black 236 (3) 213 (3) 23 (4) 0.15
White 7734 (83) 7199 (83) 535 (84) –
Asian 613 (7) 580 (7) 33 (5) –
Other 723 (8) 675 (8) 48 (8) –
Region
North America 2146 (23) 2006 (23) 140 (22) 0.01
Europe 4909 (53) 4590 (53) 319 (50) –
Asia 552 (6) 522 (6) 30 (5) –
Latin America 1406 (15) 1281 (15) 125 (20) –
Other 293 (3) 268 (3) 25 (4) –
Current smoker 1025 (11) 922 (11) 103 (16) <0.001
Medical history
Coronary heart disease† 2626 (28) 2295 (27) 331 (52) <0.001
Cerebrovascular disease‡ 736 (8) 638 (7) 98 (15) <0.001
Peripheral arterial disease§ 309 (3) 254 (3) 55 (9) <0.001
Chronic obstructive pulmonary disease 451 (5) 385 (4) 66 (10) <0.001
Heart failure 331 (4) 269 (3) 62 (10) <0.001
Hypertension 7216 (78) 6710 (77) 506 (79) 0.30
Renal dysfunction¶ 90 (1) 66 (1) 24 (4) <0.001
Pulmonary embolism or deep venous thrombosis 129 (1) 108 (1) 21 (3) <0.001
Family history of premature coronary heart disease 1544 (17) 1427 (17) 117 (18) 0.23
Family history of diabetes 3547 (38) 3324 (38) 223 (35) 0.08
Clinical features
Weight (kg) 83.6 (17.2) 83.5 (17.2) 84.9 (17.4) 0.04
Body mass index (kg/m2) 30.5 (5.4) 30.5 (5.4) 30.3 (5.4) 0.17
Waist circumference (cm) 101.1 (13.6) 100.9 (13.6) 103.2 (13.8) <0.001
Height (cm) 165.4 (9.9) 165.3 (9.9) 167.3 (9.7) <0.001
Systolic blood pressure (mm Hg) 139.7 (17.5) 139.5 (17.2) 141.6 (20.1) 0.04
Diastolic blood pressure (mm Hg) 82.6 (10.2) 82.6 (10.2) 82.0 (10.9) 0.10
Pulse pressure (mm Hg) 57.1 (13.9) 56.9 (13.7) 59.6 (15.7) <0.001
Left ventricular hypertrophy 268 (3) 236 (3) 32 (5) 0.001
Heart rate (bpm) 70.1 (10.6) 70.2 (10.5) 69.1 (11.6) 0.004
Atrial fibrillation or flutter 356 (4) 298 (3) 58 (9) <0.001
Laboratory
Fasting glucose (mmol/l) 6.1 (0.5) 6.1 (0.5) 6.1 (0.5) 0.83
2 h glucose (mmol/l) 9.2 (0.9) 9.2 (0.9) 9.3 (0.9) 0.01
HbA1c (%) 5.8 (0.4) 5.8 (0.4) 5.9 (0.5) <0.001
eGFR (ml/min/1.73 m2) 80.5 (18.1) 80.8 (18.0) 76.3 (19.9) <0.001
Urine albumin/creatinine ratio (log units) 0.1 (1.2) 0.1 (1.1) 0.4 (1.3) <0.001
LDL cholesterol (mmol/l) 3.3 (0.9) 3.3 (0.9) 3.3 (1.0) 0.72
HDL cholesterol (mmol/l) 1.3 (0.3) 1.3 (0.3) 1.2 (0.3) <0.001
Triglycerides (mmol/l) 1.9 (1.1) 1.9 (1.1) 2.0 (1.1) 0.11
Haemoglobin (g/l) 147 (13) 147 (13) 147 (14) 0.19
Sodium (mmol/l) 142.4 (2.5) 142.4 (2.5) 142.4 (2.8) 0.76
ECG
Normal 4525 (49) 4316 (50) 209 (33) <0.001
Clinically insignificant abnormality 3326 (36) 3090 (36) 236 (37) –
Clinically significant abnormality 1455 (16) 1261 (15) 194 (30) –
*Not listed in table but also included in predictive models: potassium, WBC, platelet count.
†Previous myocardial infarction, angina, positive stress test, coronary revascularisation.
‡Stroke, transient ischaemic attack.
§Limb or foot amputation, intermittent claudication, limb arterial bypass procedure.
¶Defined using a combination of preferred and low-level MedDRA terms selected by medically qualified personnel. Data presented as (N (%)
or mean (SD)).
eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein;
NAVIGATOR, Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research; WBC, white blood cell.
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Table 2 Predictors of the composite cardiovascular outcome in NAVIGATOR participants as identified in a multivariable Cox
proportional hazard stepwise selection model
Variable HR (95% CI) Wald χ² p Value
Coronary heart disease* 2.10 (1.76 to 2.50) 68.8 <0.0001
Gender (male vs female) 1.89 (1.55 to 2.29) 40.9 <0.0001
Age (per 10 years) 1.32 (1.17 to 1.48) 21.4 <0.0001
Current smoker 1.64 (1.32 to 2.04) 19.5 <0.0001
Significantly abnormal vs normal ECG 1.59 (1.28 to 1.97) 17.6 <0.0001
LDL cholesterol 1.19 (1.09 to 1.30) 15.9 <0.0001
Cerebrovascular disease* 1.56 (1.25 to 1.95) 15.5 <0.0001
eGFR (per 10 unit decrease below 60 ml/min/1.73 m2) 1.31 (1.13 to 1.51) 12.6 0.0004
Peripheral artery disease* 1.65 (1.24 to 2.19) 11.6 0.0007
Pulmonary embolism/deep vein thrombosis 2.12 (1.36 to 3.31) 10.9 0.0010
Urine albumin/creatinine ratio (log units) 1.10 (1.03 to 1.17) 9.1 0.0025
Latin America vs North America 1.48 (1.15 to 1.92) 9.0 0.0027
Pulse pressure (per 1 mm Hg) 1.01 (1.00 to 1.01) 7.8 0.0051
Chronic obstructive pulmonary disease 1.44 (1.10 to 1.88) 7.1 0.0077
Black vs all other races 1.75 (1.13 to 2.71) 6.3 0.0123
Heart failure 1.43 (1.07 to 1.90) 5.9 0.0150
Haemoglobin (per 10 g/l decrease) 1.09 (1.02 to 1.16) 5.8 0.0158
Sodium (1 unit decrease below 140 mmol/l) 1.11 (1.02 to 1.20) 5.5 0.0185
Waist circumference (per 10 cm) 1.08 (1.01 to 1.15) 5.4 0.0197
Atrial fibrillation or flutter 1.34 (1.01 to 1.79) 4.0 0.0463
Other vs North America 1.40 (0.91 to 2.15) 2.3 0.1285
Insignificantly abnormal vs normal ECG 1.11 (0.91 to 1.35) 1.1 0.3000
Europe vs North America 0.92 (0.74 to 1.14) 0.6 0.4391
Asia vs North America 0.90 (0.59 to 1.37) 0.2 0.6268
*For definitions see table 1 footnote.
eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; NAVIGATOR, Nateglinide and Valsartan in Impaired Glucose
Tolerance Outcomes Research.
Table 3 Predictors of cardiovascular death in NAVIGATOR participants as identified in a multivariable Cox proportional
hazard stepwise selection model
Variable HR (95% CI) Wald χ² p Value
Age (per 10 years) 1.77 (1.47 to 2.12) 37.6 <0.0001
Latin America vs North America 2.68 (1.82 to 3.96) 24.6 <0.0001
Coronary heart disease* 2.04 (1.53 to 2.72) 23.9 <0.0001
Heart failure 2.27 (1.56 to 3.30) 18.3 <0.0001
Gender (male vs female) 1.90 (1.41 to 2.57) 17.5 <0.0001
Current smoker 2.00 (1.41 to 2.83) 15.1 0.0001
Significantly abnormal vs normal ECG 2.01 (1.38 to 2.92) 13.3 0.0003
eGFR (per 10 ml/min/1.73 m2 decrease below 60 ml/min/1.73 m2) 1.42 (1.16 to 1.75) 11.1 0.0009
Urine albumin/creatine ratio (log units) 1.16 (1.06 to 1.27) 10.1 0.0015
Cerebrovascular disease* 1.72 (1.23 to 2.40) 10.0 0.0016
Atrial fibrillation or flutter 1.81 (1.24 to 2.65) 9.4 0.0021
Haemoglobin (per 10 g/l decrease) 1.15 (1.04 to 1.27) 7.4 0.0066
Chronic obstructive pulmonary disease 1.70 (1.16 to 2.49) 7.4 0.0066
Insignificantly abnormal vs normal ECG 1.60 (1.13 to 2.26) 7.1 0.0076
Other vs North America 2.32 (1.23 to 4.40) 6.7 0.0098
Peripheral artery disease* 1.66 (1.08 to 2.55) 5.4 0.0203
Renal dysfunction 1.97 (1.09 to 3.56) 5.0 0.0250
Asia vs North America 0.66 (0.30 to 1.47) 1.0 0.3090
Europe vs North America 1.05 (0.74 to 1.48) 0.1 0.7993
*For definitions see table 1 footnote.
eGFR, estimated glomerular filtration rate; NAVIGATOR, Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research.
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prognostic model was 0.82. When study treatments were
forced into the model, neither displayed a signiﬁcant
association and the impact on the predictive capabilities
of the other variables was negligible (data not shown).
The c-statistic for a predictive model including only clas-
sical risk factors was 0.71.
Distribution of risk in the NAVIGATOR trial population
A calibration plot which allows comparison of the pre-
dicted and observed risk of experiencing a cardiovascu-
lar event is provided in online supplementary ﬁgure S1.
Approximately 37.5% of participants were at greater
than 5% calculated risk of a cardiovascular event over
5 years, and 3.5% were at greater than 20% calculated
risk of an event over 5 years. Although the model was
developed for all NAVIGATOR participants, it could also
be applied to those with no known cardiovascular
disease, as indicated by the general lack of interaction
for variables between those with and without cardiovas-
cular disease at baseline (see online supplementary
table S1) and by the good model calibration for the
primary prevention group (see online supplementary
ﬁgure S2).
Use of cardiovascular risk reducing agents according to
calculated cardiovascular risk
Baseline characteristics of NAVIGATOR participants
divided into those with and without baseline cardiovas-
cular disease, with the latter group split further into
those at low, intermediate and high (>10%) calculated
risk, are provided in the online supplementary table S2.
There were signiﬁcant differences between those
without cardiovascular disease at high risk compared to
those at low and intermediate risk as expected.
Prescription of antihypertensive agents at baseline
increased progressively from 63% in the low-risk primary
prevention group to 86% in those with cardiovascular
disease (see table 4). β-Blockers were used twice as com-
monly in patients with established cardiovascular disease
as in the lowest risk category of those without. Similarly,
ACE inhibitors were used relatively much more com-
monly in those with established cardiovascular disease
than in low-risk patients without (although their overall
use was low in absolute terms, possibly because of the
trial exclusion criteria). Aspirin was used for secondary
prevention in 69% of participants with cardiovascular
disease whereas relatively few participants took aspirin
for primary prevention. For secondary prevention 57%
of participants were on lipid-lowering therapy. There was
an inverse relationship between use of lipid-lowering
therapy and calculated cardiovascular risk in the
primary prevention cohort; 33%, 26% and 21% were on
these agents in the low-risk, intermediate-risk and high-
risk groups, respectively.
DISCUSSION
In this analysis of NAVIGATOR, a large randomised trial
in subjects with IGT at an elevated risk of cardiovascular
events, risk factors most strongly associated with future
cardiovascular events largely reﬂected the same factors
identiﬁed in general populations and in patients with
diabetes.1 2 5–8 However, neither fasting plasma glucose,
2 h postchallenge glucose nor HbA1c was independently
associated with incident cardiovascular events.
Approximately 40% of participants in NAVIGATOR were
at greater than 5% 5-year risk. While treatment at base-
line with antihypertensive agents and other risk-reducing
drugs increased progressively with increasing predicted
risk, the trend in use of lipid-lowering therapy was in the
opposite direction (and use of this treatment and other
preventive drug therapies such as aspirin therapy were
relatively uncommon overall). This may indicate that
physicians are unsure about how to risk-stratify patients
with IGT and that a risk-stratiﬁcation tool would be
useful for this growing population’s contribution to the
overall burden of cardiovascular disease.
Several studies have estimated the increased cardio-
vascular risk of individuals with IGT, compared with
Table 4 Use of cardiovascular risk-lowering agents at baseline according to estimated cardiovascular risk (n (%))
Medications
History of cardiovascular disease at baseline?
p Value for trend
No
Low risk* (n=2398)
Intermediate risk*
(n=3580)
High risk*
(n=153) Yes (n=3175)
α-Blocker 101 (4.2) 264 (7.4) 13 (8.5) 199 (6.3) <0.001
ACE inhibitor 27 (1.1) 77 (2.2) 10 (6.5) 562 (17.7) <0.001
β-Blocker 712 (29.7) 1056 (29.5) 53 (34.6) 1845 (58.1) <0.001
Calcium channel blocker 603 (25.1) 1172 (32.7) 57 (37.3) 1180 (37.2) <0.001
Diuretic 750 (31.3) 1194 (33.4) 57 (37.3) 959 (30.2) 0.018
Any antihypertensive 1511 (63.0) 2464 (68.8) 112 (73.2) 2729 (86.0) <0.001
Aspirin 429 (17.9) 759 (21.2) 42 (27.5) 2195 (69.1) <0.001
Lipid-lowering agent 794 (33.1) 942 (26.3) 32 (20.9) 1809 (57.0) <0.001
*Cardiovascular risk derived from the prognostic model derived in NAVIGATOR; low risk refers to <5% experiencing the composite
cardiovascular event over 10 years, intermediate risk 5–20% and high risk >20%.
NAVIGATOR, Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research.
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subjects with normoglycaemia. In a recent systematic
review, IGT was associated with 20% higher cardiovascu-
lar risk compared with normoglycaemia after adjustment
for established cardiovascular risk factors (age, smoking
status, blood pressure and lipid levels)2 and data from
the DECODE study showed a 34% increase in the risk of
cardiovascular death in individuals with IGT after adjust-
ment for established risk factors.1 In NAVIGATOR parti-
cipants, expected independent predictors of events
included previous history of cardiovascular disease, male
gender, older age, current smoker status, higher LDL
cholesterol and higher pulse pressure. Regarding renal
biomarkers, each of lower eGFR and higher UACR were
also independently associated with cardiovascular events.
We found a number of other variables to be predictive
of cardiovascular events, including COPD, atrial ﬁbrilla-
tion, lower haemoglobin and previous pulmonary
embolism or deep venous thrombosis, some of which
have also been associated with cardiovascular risk in dia-
betes populations.8 A relationship between COPD and
cardiovascular events has been reported previously13 14
and, while this association is not fully explained,
smoking is clearly a common risk factor. Atrial ﬁbrilla-
tion has been shown to improve risk prediction in both
general populations and in type 2 diabetes and has
recently been incorporated into risk algorithms.5
Anaemia has been associated with higher cardiovascular
risk, particularly in patients with chronic kidney disease,
but results have been mixed in studies of unselected
populations.15–18 Survivors of hospital admissions for
pulmonary embolism have been shown to have a sub-
stantial risk for subsequent cardiovascular death in
cohort studies.19 Participants from Latin America were
also at particularly an elevated risk.
Studies of patients with diabetes and general popula-
tions have suggested that measures of glycaemia, espe-
cially higher HbA1c and postchallenge glucose, are
associated with higher cardiovascular risk.1 6 20 In our
study, no measure of glycaemia (HbA1c, fasting plasma
glucose, 2 h postchallenge glucose) was independently
associated with or predictive of cardiovascular events.
This may reﬂect the design of NAVIGATOR which spe-
ciﬁcally recruited individuals with IGT, with the result
that the ranges of values for the three glycaemic vari-
ables were relatively narrow. This suggests that while
identifying individuals with IGT may be of clinical value,
reﬁning risk prediction by further categorising accord-
ing to measures of glycaemia is probably not clinically
worthwhile. Interestingly, while higher pulse pressure
was predictive of events, other related variables (systolic
and diastolic blood pressure, hypertension and left
ventricular hypertrophy) were not predictive. HDL
cholesterol levels and heart rate also failed to improve
prediction.
As expected, the proportion of individuals treated
with antihypertensive therapies increased progressively
according to calculated cardiovascular risk and was
highest in those with known cardiovascular disease.
Recent meta-analyses have suggested that aspirin therapy
is best targeted at those with established cardiovascular
disease21 and data for the NAVIGATOR participants
largely reﬂected this. However, the use of lipid-lowering
therapies for secondary prevention was relatively low
(57%) which may reﬂect variations between participat-
ing countries in statin use, the fact that statin use at
the start of NAVIGATOR was not as widespread as it is
now, and the absence of data for cholesterol levels
prior to the start of lipid-lowering therapies. In those
with no history of cardiovascular disease, the use of
lipid-lowering therapies was sparse in those at highest
calculated risk (21%). This suggests that there is a need
to better identify and/or treat those with IGT at highest
risk, something that may be better achieved when con-
sidering classical cardiovascular risk factors as well as the
many other risk factors identiﬁed here.
This study has a number of strengths and weaknesses.
It is the ﬁrst study to examine predictors of cardiovascu-
lar risk speciﬁcally in individuals with IGT on a large
scale. Cardiovascular events were adjudicated independ-
ently. IGT was conﬁrmed biochemically in a standar-
dised manner though only a single OGTT was
performed at baseline. However, NAVIGATOR partici-
pants either had a history of cardiovascular disease or
were at high risk and so these data may not be directly
applicable to all individuals with IGT. We also examined
a composite cardiovascular endpoint and study of spe-
ciﬁc cardiovascular endpoints may have provided add-
itional information, although statistical power would be
limited. There were relatively few cardiovascular deaths
with the result that applying a predictive model with
many variables had the potential of over-ﬁtting the
model. Finally, we were not able to validate our results
by comparison with participants from a separate study.
In summary, the most powerful independent predic-
tors of cardiovascular events in a trial population with
IGT at high cardiovascular risk included classical risk
factors as well as other factors such as reduced glomeru-
lar ﬁltration rate, higher urine albumin excretion and
pre-existing thromboembolic disease, atrial ﬁbrillation,
heart failure and chronic obstructive pulmonary disease.
Prognostic models showed that consideration of these
variables would allow effective identiﬁcation of high-risk
individuals with IGT. However, measures of glycaemia
were not independently associated with cardiovascular
events. Finally, our data identify a need to better identify
patients with IGT at high-cardiovascular risk to facilitate
more aggressive management with statins and other car-
diovascular risk-reducing agents.
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